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Background: Understanding of iron oxide nanoparticles (IONP) interaction with the body 
milieu is crucial to guarantee their efficiency and biocompatibility in nanomedicine. Polymer 
coating to IONP, with polyethyleneglycol (PEG) and polyvinylpyrrolidone (PVP), is an accepted 
strategy to prevent toxicity and excessive protein binding. 
Aim: The aim of this study was to investigate the feature of IONP adsorption of complement 
proteins, their activation and consequent inflammatory response as a strategy to further elucidate 
their biocompatibility.
Methods: Three types of IONP with different surface characteristics were used: bare (IONP-
bare), coated with PVP (IONP-PVP) and PEG-coated (IONP-PEG). IONPs were incubated with 
human plasma and adsorbed proteins were identified. BALB/c mice were intravenously exposed 
to IONP to evaluate complement activation and proinflammatory response. 
Results: Protein corona fingerprinting showed that PEG surface around IONP promoted a 
selective adsorption of complement recognition molecules which would be responsible for the 
complement system activation. Furthermore, IONP-PEG activated in vitro, the complement 
system and induced a substantial increment of C3a and C4a anaphylatoxins while IONP-bare 
and IONP-PVP did not. In vivo IONP-PEG induced an increment in complement activation 
markers (C5a and C5b-9), and proinflammatory cytokines (IL-1β, IL-6, TNF-α). 
Conclusion: The engineering of nanoparticles must incorporate the association between comple-
ment proteins and nanomedicines, which will regulate the immunostimulatory effects through a 
selective adsorption of plasma proteins and will enable a safer application of IONP in human therapy.
Keywords: iron oxide nanoparticles, complement, inflammatory response, protein corona
Introduction
Iron oxide nanoparticles (IONP) have been subject of intensive research for many 
years due to their intrinsic properties for which they are used in nanomedicine as 
contrast agents,1 hyperthermia inductors,2 and drug-delivery carriers.3 However, 
despite the initial enthusiasm to popularize and spread their use in biomedical areas, 
promising candidates previously approved by the Food and Drug Administration 
have been withdrawn due to hypersensitivity and toxicity concerns.4,5 One of the 
major pitfalls of IONP-based nanomedicines is the lack of biocompatibility with 
blood components and the immune system. When IONP and other nanomedicines are 
injected into the bloodstream, proteins and other biomolecules are rapidly adsorbed 
on their surface creating a novel biological entity which will would be dependent 
of nanoparticle (NP) physicochemical properties.6,7 This newly formed complex, 
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known as “protein corona” (PC), shapes the biological 
interaction between the IONP with other biomolecules, 
cells, and physical barriers.8
Moreover, the interaction of IONP with components 
of the immune system such as phagocytic cells, and the 
complement system are key modulators for their efficacy 
distribution and toxicity.9,10 The complement system is a 
group of ~30 proteins (distributed as soluble elements in 
plasma and as extracellular receptors in immune cells) that 
provides critical immunoprotective and immunoregulatory 
functions; it opsonizes and induces a series of inflammatory 
processes against pathogens and nanostructured materials, 
which are perceived as foreign agents.11 The complement 
system can be triggered through three different pathways: 
1) the classic pathway, activated by the immune complexes 
(antigen–antibody) and by others molecules such as reactive 
protein C, 2) the lectin pathway, activated by the union of 
the mannan-binding lectin (MBL) or ficolins to the mannose-
containing carbohydrates or N-acetylglucosamine, and 3) the 
alternative pathway that can be spontaneously initiated when 
the complement component C3 binds to a reactive surface.12 
Although complement pathways depend on different mol-
ecules for their initiation, they converge to generate the same 
set of effector molecules. Anaphylatoxins (C3a, C4a, and 
C5a) are soluble byproducts of the complement activation 
that are potent inflammatory inductors. When these peptides 
are produced in an uncontrolled condition, they can induce 
a wide spectrum of side effects such as cardiac and respira-
tory complications.13 Some nanomedicines, such as Doxil,14 
nanomaterials such as carbon nanotubes (CNT),15 and IONP16 
have shown the potential to interact with the complement 
system resulting in a significant activation. Consequently, 
evaluation of the complement system has recently gained 
attention in nanomedicine development since its activation 
has been linked to numerous adverse effects in animal models 
and patients.12,13,17
In this study, we aimed to test whether the use of poly-
meric coatings on IONP is capable of adsorbing specific 
proteins to modulate the complement activation and if this 
interaction would be translated to an inflammatory response. 
Through characterization of the human PC, we demonstrate 
that polyethyleneglycol (PEG) coating on IONP promoted a 
selective adsorption of complement recognition molecules, 
which would be responsible for the complement system 
activation. These observations will help to gain insight on 
how nanomedicines interact with the proteins of the immune 
system and to develop potential strategic interventions to 
modulate (inhibiting or stimulating) complement activation 
in vivo to increase therapeutic applications of IONP.
Materials and methods











(IONP-bare) were a kind gift from Dr Jaime Santoyo 
(Physics Department, Cinvestav-IPN), and were synthesized 
as previously described.18 Polyvinylpyrrolidone- (PVP) and 
PEG-coated IONP were purchased from Sigma Aldrich 
(St Louis, MO, USA). IONP were examined by transmis-
sion electron microscope (TEM), JEM2010 (JEOL Ltd.) for 
particle morphology and size distribution in TEM mode and 
elemental mapping by energy-dispersive X-ray spectroscopy. 
Hydrodynamic particle size distributions were measured by 
centrifugal liquid sedimentation in a DC24000 system (CPS 
Instruments Inc.) A certified polyvinyl chloride particle 
calibration standard provided by the instrument supplier, was 
used to calibrate all measurements. Zeta potential of IONP 
was analyzed by Laser Doppler microelectrophoresis using 
the Zetasizer Nano ZS90 size analyzer (Malvern Instruments 
Ltd.). The endotoxin content was assessed by the endpoint 
chromogenic Limulus Amebocyte Lysate. The three IONP 
were negative for endotoxin contamination (,0.1 EU/mL).
PC formation and protein identification
IONP were incubated with pooled human plasma (2.5 mg/mL) 
at 37°C for 30 minutes. This temperature was chosen to 
emulate the physiological conditions in the bloodstream and 
to functionally evaluate complement in vitro.19 Unbound 
proteins were removed after centrifugation at 22,000× g for 
30 minutes followed by three washing steps with PBS-EDTA. 
The resulting IONP–protein complex is considered as the 
“hard corona,” which consists of those proteins adsorbed on 
the NP surface for enough time to influence the NPs interac-
tions with living system.20 Proteins were desorbed from IONP 
by incubation with LDS Sample Buffer (Novex) at 70°C for 
10 minutes. Then, the total recovered protein of each IONP 
was separated by one-dimensional SDS-PAGE 4%–12% 
Bis–Tris polyacrylamide gels.21,22 The lanes were cut into 
fractions23 (Figure S1) and prepared for further analysis by 
reduction, alkylation, and tryptic digestion (trypsin-LysC, 
37°C, overnight).24 The peptide extracts were analyzed on a 
nanoliquid chromatography system (Acquity UPLC, Waters), 
coupled by an electrospray ionization interface to a linear 
ion trap mass analyzer (LTQ values, Thermo). The raw files 
were converted to mzML HUPO standard archives using the 
ProteoWizard converter.25 The protein search was performed 
with Comet26 against a Uniprot fasta database for Homo 
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peptide and protein hits were validated using PeptideProphet/
ProteinProphet,28,29 and converted to the final result files. 
The complete bioinformatic workflow was implemented in 
taverna (https://taverna.incubator.apache.org/),30 running on 
massypup64.30 The mass spectrometry proteomics data have 
been deposited to the ProteomeXchange Consortium (http://
www.proteomexchange.org/)31 via the PRoteomics IDEnti-
fications (PRIDE) partner repository (http://www.ebi.ac.uk/
pride/archive/)32 with the dataset identifier PXD004441. The 
complete list of identified proteins is listed in Table S1.
Pc biological analysis using cluegO
ClueGO, a Cytoscape plug-in (version 2.2.5), was employed 
to analyze, classify, and visualize the network of bio-
logical process related to each PC.33 Data were analyzed by 
hypergeometric test and P-value correction with the Bonferroni 
step down. Global Homo sapiens was used as a background 
annotation database and Gene Ontology terms were visualized 
as nodes linked base on their kappa score level (0.5).
complement activation in human plasma
Blood plasma samples were obtained from 30 healthy volun-
teer donors by venipuncture of whole blood. Samples were 
pooled, aliquoted, and stored at -80°C until use. IONP were 
dispersed at 1 mg/mL in plasma and incubated for 30 minutes 
at 37°C. After that, cold EDTA was added (at 10 mM final 
concentration) to stop all the complement activation pathways. 
Protein–IONP complexes were separated by centrifugation 
at 15,000× g for 30 minutes at 4°C. After that, C3a, C4a, and 
C5a concentrations were determined in plasma samples with 
the Cytometric Bead Array Human Anaphylatoxin Kit (Cat 
No 561418, Becton Dickinson), which measures both C3a, 







). Informed consent was obtained in writing from 
each participant prior to inclusion in the study, which was 
performed in accordance with the Declaration of Helsinki and 
according to institutionalized bioethics code. The procedure 
followed for extracting plasma proteins from human blood 
is classified as research with minimal risk according to the 
current Regulation of the General Health Law in the Field of 
Health Research, Art 17, and does not require approval from 
an institutional research ethics committee.
In vivo complement activation
Male BALB/c mice (7–8 weeks old) were randomly assigned 
into four experimentation groups (five mice per group): 1) con-
trol (sterile 0.9% NaCl solution); 2) exposed to IONP-bare; 
3) exposed to IONP-PVP; and 4) exposed to IONP-PEG. 
Then, mice were anesthetized under 3% isoflurane/oxygen 
mixture. Mice were intravenously injected by the lateral tail 
vein at a dose of 5 mg NP/kg body weight. The selected dose 
of 5 mg/kg of body weight is in agreement with a high dose 
achieved in Phase II clinical studies of IONP used for MR 
angiography.34,35 A pilot study with Zymosan A, a known acti-
vator of the complement system, was performed to determine 
a time point where a significant complement activation occurs. 
Based on our results, the order and timeline of the hypoth-
esized biological events (complement activation – increment 
of cytokines), and previous literature,17,36 we chose 90 minutes 
as exposure time in order to evidence an increment of both 
the complement markers and cytokines. After exposure, 
mice were deeply anesthetized and euthanized by terminal 
exsanguination (intracardiac puncture). Liver, spleen, kidney, 
heart, and brain were extensively washed in saline solution 
and collected for Fe biodistribution analysis. Plasma concen-
trations of sC5a and sC5b-9 were determined by ELISA with 
commercial kits (Mouse Complement Component C5a assay 
kit Cat; DY2150, R&D Systems Inc., and Mouse Terminal 
Complement Complex C5b-9 Kit Cat; CSB-E08710m Cusa-
bio Biotech Co. Ltd., respectively). Levels of TFN-α, IL-1β, 
and IL-6 were measured with a multiplexed cytokine assay 
(Mouse Magnetic Panel catalog no. LMC0001M, Novex; Life 
Technologies), following the manufacturer’s instructions. 
Quantification of Fe in the tissues was performed by particle-
induced X-ray emission (PIXE) following a methodology 
previously described.37 PIXE measurements were validated 
with two standards from the International Atomic Energy 
Agency (IAEA 153 and IAEA 155). All animal experimental 
procedures were approved by the Institutional Committee for 
the Care and Use of Laboratory Animals at CINVESTAV-
IPN that follows the regulations established by the Mexican 
Official Norm for the Use and Welfare of Laboratory Animals 
(NOM-062-ZOO-1999), which is in accordance with the 
Guide for the Care and Use of Laboratory Animals, USA.
statistical analysis
Data analysis was performed using GraphPad Prism 6 
(GraphPad Software Inc.). Normal distribution of the data 
was tested with Shaphiro–Wilk test. Comparison between 
experimentation groups was analyzed by one-way ANOVA 
followed by Dunnett’s post hoc test. Differences with P,0.05 
were considered statistically significant. Data are presented 
as the mean ± standard error of the mean (SEM).
Results
Physicochemical characterization of IONP
IONP were characterized as pristine material TEM (Figure 1). 
The three IONP nanoparticles showed a diameter range 
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showed the absence of contamination with other elements 
rather than iron and oxygen. The IONP were characterized 
suspended in physiological sterile saline solution since this 
was the vehicle used for corona formation and complement 
activation assays. The hydrodynamic diameter measurements 
showed that three IONP tend to spread within two size popula-
tions, the smaller (few nanometers) corresponding to primary 
particles and a larger one corresponding to agglomerates 
of primary particles (Table 1). The percentages of primary 
particles that remain after IONP suspension were: 71.2% 
for IONP-bare, 83.3% for IONP-PVP, and 65.1% for IONP-
PEG. Compared to IONP-bare and IONP-bare, the IONP-
PVP particles suspended in saline media were less susceptible 
to form low-sized agglomerates from primary particles.
Protein adsorption to IONP surface
In order to identify the adsorbed proteins onto the three 
IONP and to determine how surface coatings influence 
the activation of the immune response, we obtained a pro-
teomic profile of the PC that surrounds the three IONP (PC 
fingerprinting) using LC-MS/MS. A total of 263 shared 
proteins (present on all three IONP) were identified and 
represented 60.59% of IONP-PEG associated proteins, for, 
64.30% for IONP-bare, and 52.9% for IONP-PVP. The set 
of non-shared proteins in the respective coronas contributed 
to the 8.5% of IONP-bare PC, 18.3% of the IONP-PVP PC, 
and 15.5% for the PC on IONP-PEG (58, 125, and 106 pro-
teins respectively) (Figure 2A). In regard of physicochemical 
properties of the proteins such as the isoelectric point (pI) 
and molecular weight (MW), we observed slight differences 
between the three IONP (Figure 2B and C). For example, 
IONP-PEG adsorbed more proteins with a pI from 5 to 6, and 
fewer proteins with a pI from 8 to 9 compared to IONP-bare 
and IONP-PVP; IONP-PEG do not have a preference for 
proteins of a particular MW (Figure 2C). IONP-bare adsorbed 
more proteins with a pI from 6 to 7 and fewer proteins with a 
Figure 1 characterization of IONP by TeM.
Notes: Micrographs of three different IONP and their size distribution (upper panel). elemental mapping by energy-dispersive X-ray spectroscopy (lower panel).
Abbreviations: IONP, iron oxide nanoparticles; Peg, polyethyleneglycol; PVP, polyvinylpyrrolidone; TeM, transmission electron microscope.
Table 1 Physicochemical characterization of IONP
Particle Primary size 
range (nm)a
Hydrodynamic size (nm)b (% of total population) Zeta potential (mV)c
Primary Agglomerates
IONP-bare 4.9–25.5 6.2±0.5 (71.21) 75±14 (19.01) -14.1±1.8
IONP-PVP 4.4–65.7 6.5±1.0 (83.36) 75.6±10.8 (0.024) -13.3±2.5
IONP-Peg 1.8–11.21 6.4±0.6 (65.1) 31.0±2.80 (31.8) -46.3±3.8
Notes: asize distribution of pristine materials reported in escamilla rivera et al.69 bsize distribution of IONP suspended in saline solution obtained by centrifugal liquid 
sedimentation (distribution based on particle number). Values are expressed as mean ± sD, and those in parenthesis represent the percentage from the total measured 
population. claser Doppler microelectrophoresis of IONP suspended in saline solution. Values are expressed as mean ± sD.
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pI ,5 than to the other two NP. Proteins with MW ,20 kDa 
were more abundant in IONP-bare and proteins from 60 to 
100 kDa were less adsorbed. While, IONP-PVP adsorbed 
more proteins with a pI .9 and high MW but in a lesser 
extent proteins of lower MW (,20 kDa) when compared to 
IONP-bare and IONP-PEG.
Regarding the identity and function of the adsorbed pro-
teins, the biological processes network of associated proteins 
on IONP-bare have a role in blood coagulation, fibrin clot 
formation, angiogenesis, regulation of cell migration, sub-
strate adhesion, and proteins related to the modulation by host 
of viral process (Figure 3A). On the other hand, IONP-PVP 
adsorbed proteins related to regulation of proteolysis, small 
GTPase, receptor-mediated endocytosis, Fc receptor-medi-
ated stimulatory signaling pathway, and negative regulation 
of wound healing (Figure 3B).
Whereas the corona of IONP-PEG showed that their 
proteins belong to the activation of the immune response, 
opsonization, lectin pathway of the complement activation, 
regulation of protein processing, platelet activation, actin 
filament organization, and the Fc signaling pathway involved 
in phagocytosis (Figure 3C). Although the three IONP-
coronas share a set of proteins that participate in particular 
biological processes, there are proteins that were exclusive to 
each coating (Table S1). For example, IONP-PEG adsorbed 
proteins involved in plasma lipoprotein particle remodeling 
(Figure 4).
complement activation in vitro
In order to test whether adsorption of complement proteins 
could translate into an activation of this system, human plasma 
was exposed to the three different IONP, and the levels of 
anaphylatoxins were measured. After 30 minutes, samples 
exposed to IONP-PEG showed a significant 2-fold incre-
ment for C3a and 4.8-fold in C5a concentration (Figure 5A 
and B). However, no evidence of change was observed for 
C4a (Figure 5C). In contrast, plasma exposed to IONP-PVP 
and IONP-bare did not induce any significant change in 
Figure 2 characteristics of recovered in the coronas of the three IONP.
Notes: Venn diagram showing the number of identified proteins and the relative percentage of each group to the total shared (A). Proteins were classified according to their 
isoelectric point (B) or molecular weight (C) and their relative percentages are shown.
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C3a, C4a, or C5a compared to control samples (Figure 5). 
Figure 5D shows a representative immunoblot of C3a com-
plement component adsorbed in PC of IONP, where the 
increment for IONP-PEG can be observed. As previously 
mentioned, complement activation pathways possess com-
mon downstream points, the excision of C4 into C4b (which 
will form the C3 convertase with C2a) and C4a is a common 
endpoint of the classical and lectin pathways. Consequently, 
the production of C3a and C5a with the absence of C4a in 
the human plasma exposed to IONP-PEG hints toward a 
complement activation that can be predominant through the 
alternative pathway.
Complement activation**
Blood coagulation, fibrin clot formation**
Complement activation, lectin pathway
Receptor-mediated endocytosis
Smooth muscle cell migration
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Substrate adhesion-dependent cell spreading**
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Figure 3 Biological processes network of associated proteins on IONP.
Notes: Gene ontology was used to group the identified proteins in the corresponding biological process using ClueGo analysis. The label of the most significant term per 
functional group is shown. IONP-bare (A), IONP-PVP (B), and IONP-Peg (C). **P,0.001 (P-value corrected with Bonferroni step-down).
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complement activation and induction 
of proinflammatory response in BALB/c 
mice exposed to IONP
Male BALB/c mice were administered with IONP to get an 
insight of the capabilities of IONP to activate the comple-
ment system and induce a proinflammatory response in vivo. 
After exposure, the plasma concentration of anaphylatoxin 
C5a in IONP-bare and IONP-PVP treated animals remained 
without changes compared to the control group (Figure 6A). 
In contrast, IONP-PEG induced a 1.3-fold increment of 
C5a in plasma of exposed mice. Quantification of sC5b-9 
showed that IONP-bare and IONP-PVP did not induce a 
significant increment (P.0.05) in the animals exposed. 
However, a 2.3-fold increment was observed in the group 
exposed to IONP-PEG (Figure 6B). The proinflammatory 
profile of cytokines showed that mice exposed to IONP-
Figure 4 Biological processes network of associated proteins on IONP-Peg Pc.
Notes: Gene ontology terms are visualized as nodes linked base on their kappa score level (0.5) using ClueGO analysis. The label of the most significant term per functional 
group is shown in bold. The node size represents the percent of associated genes of proteins per node.
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bare and IONP-PVP did not exhibit significant increments 
in IL-1β, TNF-α or IL-6 concentrations vs the control group 
(Figure 6C). While the group exposed to IONP-PEG showed a 
1.60-fold increment of IL-1β, 5.7-fold in TNF-α and 2.6-fold 
of IL-6 compared to the control group. PIXE measurements 
revealed that animals exposed to IONP-PEG accumulate 
higher concentrations of NP in the liver, spleen, and kidney 
(2.3-fold, 1.57-fold, and 1.43-fold, respectively) compared 
to control (Figure 6D). IONP-bare induced an increment in 
the iron content of the liver (1.77-fold) compared to control 
group. IONP-PVP did not induce a significant change (com-
pared to control) of iron concentration in the selected organs 
(P.0.05). Given that in such short exposure times IONP 
dissolution is negligible and the PIXE technique allows the 
quantification of iron in whole organs,37,38 the retention of 
initial dose was calculated taking into account the weight of 
the organs, the concentration of iron in the control, and the 
IONP dose administered to each animal. These estimations 
showed that IONP-PEG are retained in larger amounts in the 
selected organs with a retention of 86% of the initial dose, 
followed by IONP-bare with 55.9% and IONP-PVP with 
33% of the administered dose.
Discussion
In this study, we investigated whether the interaction of 
plasma proteins with different coatings on IONP is capable 
of triggering an adverse effect, namely the proinflammatory 
response in an in vivo and in vitro model. Despite the fact that 
PEG grafting is considered as a highly hydrophilic coating 
that can prevent nonspecific protein adsorption, in the last 
decade, several reports have shown that PEG and PEGylated 
nanoformulations can elicit complement activation, which 
is in agreement with the observed results in this study. For 
instance, Hamad et al39 demonstrated that PEG molecules of 
increasing MW were capable of binding complement pro-
teins, enhancing the alternative pathway turnover, and prob-
ably to bind directly to L-lectins to further activate the lectin 
pathway. Moreover, Yang et al40 observed that the grafting 
of polymeric NP with different PEG sizes reduced protein 




Figure 5 IONP-Peg activates the complement system and increases the anaphylatoxin concentration in human blood plasma.
Notes: Quantification of complement activation products by ELISA: levels of anaphylatoxin C3a (A), terminal complement complex, c5a (B), and terminal complement 
complex, c4a (C) in human plasma. each bar represents the mean ± SEM of three independent experiments. *Statistically significant difference vs control, *P,0.05 aNOVa 
post hoc Dunnett’s test. representative immunoblot of c3 complement component adsorbed in protein corona of IONP (D).
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activation and complement-mediated phagocytosis in human 
and mouse macrophages. Activation of the complement 
system by PEG coating on IONP could be achieved by direct 
or indirect mechanisms such as the specific recognition by 
anti-PEG IgG
2
 and IgM specific antibodies that could initiate 
the classical pathway.41 Also, PEGylated nanostructures can 
interact directly with complement proteins; particularly, if 
the C3 component is trapped inside the hydrated structure of 
PEG, the conformational changes of C3 and its spontaneous 
hydrolysis could be accelerated leading to the assembly of the 
fluid-phase C3 convertase C3bB.42 Moreover, Szebeni et al43 
have proposed that the exposed hydroxyl groups at the end 
of PEG structures could act as molecular anchors for C3b 
and thus initiate the alternative pathway.
Recent studies focused on magnetic NP have reported 
that size, charge, surface, polymer conformation, and 
molecular structure influences protein adsorption. For 
example, Hu et al44 reported an effect of the primary size 
on the composition and abundance of proteins on pristine 
IONP; at smaller sizes (,30 nm) NP adsorbed fewer proteins 
from FBS and displayed different composition comparing 
to IONP of 200 and 400 nm. In contrast, in this study, we 
did not observe a relation between size and the amount 
or identity of proteins adsorbed. In regard to the surface 
charge, Sakulkhu et al45 observed that positively charged 
IONP coated with polyvinyl alcohol or dextran adsorbed 
more proteins from FBS rather than ones with a negative 
charge. In contrast, IONP used in this study had a negative 
charge and the most abundant proteins in physiological 
conditions at pH 7.4 are negative; in particular, IONP-PEG 
adsorbed more proteins with a pI from 5 to 6 and their zeta 
potential was the highest negative -46.3 mV compared 
to the other two IONP. Moreover, Hofmann46 proposed 
that protein positive-charge domains could mediate these 
interactions, protein–particle, protein–protein interactions 
as well as protein conformational change and denaturation. 
These results demonstrated that PC depends on the entire 
physicochemical characteristics of IONP and suggest that 
electrostatic force is not the only factor that can modulate 
protein adsorption on IONP.
β α
Figure 6 IONP-PEG activates the complement system and induces a proinflammatory response in mice.
Notes: Quantification of complement activation products by ELISA: levels of anaphylatoxin C5a (A) and terminal complement complex, c5b-9 (B), in plasma of BalB/c 
mice. Levels of circulating proinflammatory cytokines (C). Biodistribution of IONP in mice exposed (D). each bar represents the mean ± seM of n=5 (*P,0.05) aNOVa 
post hoc Dunnett’s test.
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The PC profiles were associated with several biological 
processes; this protein fingerprinting gives an insight into 
responses that potentially could be triggered by IONP such 
as blood coagulation, complement activation, regulation 
of protein processing, lipid metabolism, and cytoskel-
eton organization. For example, IONP-bare adsorbed ex 
situ proteins related to blood coagulation and angiogen-
esis. It has been reported that IONP adsorbed coagulation 
factor VII and fibrinogen,45 which can activate the kallikrein 
system. In this regard, Simberg et al47 demonstrated that 
amine-modified IONP adsorb plasma kallikrein and high 
molecular weight kininogen and induce thrombosis and 
activation of the kallikrein–kinin system in vivo. On the 
other hand, IONP-PVP adsorbed proteins related to regula-
tion of proteolysis (associated with blood coagulation) and 
the Fc receptor-mediated stimulatory signaling pathway, 
which could potentially modify the risk of intravascular 
coagulation or incidents of vascular thrombosis.48 More-
over, nanomedicines could exacerbate some pathologies by 
impairment or depletion of plasma proteins. For example, the 
adsorption of lipoproteins is related to hypercholesterolemia 
and a higher risk of atherosclerosis. Muller et al49 observed 
that lipoproteins that are adsorbed to polystyrene NP dis-
integrate. Also, proteins adsorbed onto redox-active NP 
can undergo denaturation by oxidation,50 which can induce 
systemic effects such as thrombosis.51,52 It is noteworthy 
that some of the unique proteins associated to IONP-PEG 
corona have a critical role in the complement activation, 
immune response, and coagulation systems. For example, 
we identified MBL2, L-ficolin, collectin-liver 1, galectin 3, 
SKAP2, and protein G6b, PDGF, Annexin V, and collagen 
alpha chain (Table S1). Particularly, the first three proteins 
are implicated in complement activation. MBL belongs to 
the collectin family and is an element in the innate immune 
system capable of activating the lectin complement path-
way.53 Also, MBL binds to late apoptotic cells and necrotic 
cells facilitating their uptake by macrophages.54 L-ficolin 
is a pattern recognition molecule that specifically binds 
to mannan, LPS, 1,3-β-glucans, and lipoteichoic acids.55 
Meanwhile, collectin-liver 1 has been recently recognized 
as a pattern recognition molecule that could interact with 
carbohydrates through its specific recognition domain and 
it’s found associated in circulation with other lectins.56 Both 
MBL2 and L-ficolin are part of the few described activators 
of the lectin pathway, associated to MASP. The resulting 
complex activates MASP, which cleaves C2 and C4 to form 
the C3b convertase.57
Altogether, MBL2, L-ficolin, and collectin-liver 1 evi-
denced that IONP-PEG induced a selective adsorption of 
complement recognition molecules, which would be the 
responsible for the complement system activation. This 
association of recognition molecules is in agreement with 
previous observations with polyethyleneoxide polymeric 
NP,58 soluble PEG,39 PEGylated CNT,59 and iron oxide 
nanoworms.60 Although the lectin pathway is a strong can-
didate to explain the route for complement activation, it 
has been reported that PEG and PEGylated CNT can also 
increase the C3 turnover leading to an amplification loop in 
the alternative pathway.39,59 In addition to complement acti-
vation proteins and immunoglobulins, we identified proteins 
implicated in the activation of immune system cells that could 
explain the proinflammatory responses at other levels. Such 
is the case of galectin, a protein that activates the inflam-
matory response in immune cells, promotes the adhesion of 
neutrophils, and promotes the phagocytosis in macrophages.61 
It is clear that after proteomic analysis for fingerprinting PC 
on nanomedicines, a next logical step is to identify whether 
the components of the PC may have a causal involvement 
in physiological disorders, a tool that could be used for both 
personalized diagnostics and therapeutic treatments.62
Although differences exist between mouse and human 
immune system, the complement system is highly conserved 
among these species.63 The main differences in these two spe-
cies are present in the proteins that modulate the amplification 
cascade rather than in proteins that participate in the trig-
gering of the proteolytic pathways.64 In agreement with our 
results, Banda et al60 demonstrated that iron oxide nanoworms 
coated with dextran induced complement activation both in 
human and mouse. However, they found that the alternative 
complement pathway is the predominant pathway in humans, 
whereas in mice the main activation occurs through the lectin 
pathway. It has been demonstrated that interspecies differ-
ences in protein-binding profiles could exist for some NP; 
however, adsorption of complement protein appears to be 
a unifying factor among PCs and the particular differences 
in the magnitude of the complement activation may be due 
to the amount of recruited complement triggering proteins.22 
The agreement between the observations in mice and humans 
opens the possibility to include systematic evaluations of 
complement activation by nanomedicines as an integral part 
of preclinical studies to use this parameter as a predictor of 
biocompatibility and bioavailability.
Our biodistribution findings are in agreement with previ-
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in the liver and spleen of exposed animals. For example 
Xue et al65 found that IONP grafted with different PEG 
MW intravenously administered in mice are rapidly cleared 
of the circulation (t
½
 15–27 minutes) and accumulated pre-
dominantly in the liver and spleen. The authors confirmed 
that in these organs, IONP did not induce visible necrosis or 
inflammatory infiltration. Moreover, Huang et al66 observed 
that regardless of the size of PVP coating, IONP are sig-
nificantly accumulated in the liver and spleen after 1 hour. 
It is possible that after internalization in the organs, IONP 
could exert an inflammatory effect through the induction of 
necrosis, increase of reactive species of oxygen, and lyso-
somal or mitochondrial damage as previously described in 
vitro. Due to our experimental approach, it is not possible 
to exclude some contribution of the cytokines originated in 
the organs. However, we postulate that given our exposure 
time (90 minutes), it is probable that the proinflammatory 
effect was generated as a response to the anaphylatoxins (the 
soluble mediators of complement activation) generated upon 
the first contact between IONP-PEG and plasma, which is in 
agreement with previous results.67 The anaphylatoxin C5a 
is the most potent proinflammatory mediator released upon 
complement activation, it has greater potency to induce hista-
mine release compared to C3a, and it acts as strong chemoat-
tract that activates and guides neutrophils, monocytes, and 
macrophages to the complement activation.68 Additionally, 
C3a and C5a trigger the proinflammatory response through 
their corresponding G-protein-coupled receptors (C3aR and 
C5aR, respectively) causing the release of proinflammatory 
cytokines such as IL-1β, TNF-α, and IL-6 in monocytes, 
macrophages, basophils, and neutrophils.11 In addition, inter-
action with their receptors stimulates oxidative metabolism 
in neutrophils, the production of ROS, and the release of 
lysosomal enzymes from various phagocytic cells.
From our results, it can be suggested that in order to 
predict systemic effects associated to the nanomedicines, it 
is not enough to know only the identity of proteins that are 
forming the PC but it is also becoming necessary to develop 
experimental approaches capable of considering the com-
plex interactions between biomolecules, immune cells, and 
nanomedicines.
Conclusion
Our results suggest that the elicited biological effects from 
the interaction with IONP are not only associated with their 
pristine properties but also to the identity of the protein–IONP 
complexes. It is highly probable that specific polymeric 
determinants, projected in the PEGylated structure of IONP-
PEG, are recognized as a pathogen associated pattern and pro-
mote their recognition by complement proteins. Additionally, 
we have shown that complement activation measurements 
in humans and mice are in agreement and could be used as 
an integral part of preclinical studies to use this parameter 
as a predictor of biocompatibility and bioavailability. The 
engineering of nanoparticles, which takes into account the 
association between complement proteins and nanomedi-
cines, will reduce the immunostimulatory effects through 
a selective adsorption of plasma proteins and will enable a 
safer application of IONP in human therapy.
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